CVS Raises 2026 Outlook After Insurance Cost Controls Drive Q1 Beat

CVS Health delivered stronger than expected first quarter results on Wednesday and lifted its full year outlook, signaling that its once struggling Aetna insurance unit is beginning to stabilize after two difficult years of elevated medical spending. The performance reflects a broader turnaround effort that has included aggressive cost cutting, leadership changes and more disciplined management of government sponsored health plans.

The company now expects adjusted earnings per share between $7.30 and $7.50 for 2026, up from its prior range of $7.00 to $7.20. It raised its revenue forecast to at least $405 billion from a previous minimum of $400 billion. Chief Financial Officer Brian Newman told reporters that most of the $5 billion increase stems from favorable trends at Aetna. All three major business lines, including the retail pharmacy chain, the Caremark pharmacy benefit manager and the insurance operation, beat Wall Street revenue projections.

Analysts had forecast full year earnings of about $7.16 per share. CVS reported adjusted first quarter profit of $2.57 per share, comfortably above the $2.20 consensus estimate compiled by LSEG. Shares rose roughly 4 percent in pre market trading.

The results mark the fifth consecutive quarter of beating expectations, a notable shift after 2024 when several high profile misses contributed to the departure of former CEO Karen Lynch. Under new leadership the company has adopted a strategy of issuing conservative guidance and then working to outperform it. Newman described the approach as deliberate. “From an investor lens, we said let’s put out realistic, reasonable targets and then find pathways to outperform,” he said. “So to beat and raise, which I think is probably the fourth or fifth consecutive, it feels like we’re delivering on that.”

Particular attention has centered on Aetna’s medical loss ratio, the share of premium revenue spent on actual medical care. The ratio fell to 84.6 percent in the first quarter, below analysts’ expectations of 87.58 percent and improved from 87.3 percent a year earlier. Lower ratios generally mean stronger profitability for insurers. Newman said the company has grown more adept at forecasting medical costs and has taken steps to tighten utilization management inside its Medicare Advantage plans, where higher than anticipated use of services had weighed on results industry wide.

Those plans, which now cover more than half of all Medicare beneficiaries, have become a focal point in Washington. The federal government pays private insurers a fixed amount per enrollee, adjusted for health status. When costs exceed those payments, taxpayers absorb the difference through subsidies. When insurers manage costs more effectively, as CVS appears to be doing, the savings can improve margins but also raise questions about whether plans are adequately meeting enrollees’ needs or simply avoiding higher acuity patients.

CVS has pursued $2 billion in overall cost reductions, closed underperforming stores and adjusted its mix of prescription drugs at Caremark to favor more profitable products. The health services segment, which includes the pharmacy benefit manager, benefited from that mix shift. Yet Newman struck a cautious tone even as he expressed confidence in the updated guidance. Medical costs remain “still too high,” he said, suggesting the company is not assuming an immediate return to pre pandemic trends.

The broader context is an American health care system that continues to consume nearly one fifth of the nation’s economic output while delivering outcomes that lag many peer countries. Large integrated players like CVS, which combine insurance, pharmacy benefits, retail clinics and mail order services, argue that their scale creates efficiencies. Critics counter that such concentration can also produce leverage over drug pricing negotiations, hospital contracts and patient choice. Pharmacy benefit managers in particular have drawn scrutiny from both progressive lawmakers and conservative antitrust enforcers for the spread between what they charge employers and what they reimburse pharmacies.

For now, CVS’s improved forecasting ability and tighter cost controls appear to be paying off. The company’s willingness to raise guidance after a period of conservative signaling suggests management believes the worst of the medical cost surge may be behind it. Yet the health insurance business remains sensitive to demographic shifts, including an aging population that requires more care, and to policy changes that could alter Medicare Advantage payment rates.

Wednesday’s report will be closely watched not only by investors but by policymakers who are once again debating how to slow the growth of federal health spending without reducing access. CVS’s progress illustrates how private insurers can respond to financial pressure, but it also underscores how much of the system’s performance still hinges on the intricate and often opaque interplay between government programs, corporate incentives and patient needs. The coming quarters will reveal whether these early signs of stabilization represent a lasting improvement or merely a temporary respite in a sector where cost pressures have proven remarkably persistent.